Clinical and microbiological effects of systemic azithromycin in adjunct to nonsurgical periodontal therapy in treatment of Aggregatibacter actinomycetemcomitans associated periodontitis: a randomized placebo-controlled clinical trial.

Objective This study aimed to evaluate clinical and microbiological effects of systemic azithromycin ( AZM) in adjunct to nonsurgical periodontal therapy ( NSPT; or scaling root planing - SRP) in treatment of Aggregatibacter actinomycetemcomitans associated periodontitis ( AAAP). Methods and materials Seventy individuals with moderate to severe periodontitis and subgingival detection of A. actinomycetemcomitans were randomly allocated to two groups. Thirty-five individuals were allocated to full mouth SRP+AZM (500 mg oral delivery ( OD) × 3 days) while 35 individuals were allocated to SRP+Placebo ( OD × 3 days) group. The clinical variables evaluated were probing depth ( PD), clinical attachment level ( CAL), gingival index ( GI), plaque index ( PI), and percent bleeding on probing sites (% BOP), while microbiologic variables included percentage of subjects positive for A. actinomycetemcomitans at baseline, 3, 6, and 12 months. Results The AZM group showed statistically significant reduction in mean PD (2.91 ± 0.88 mm) as compared to placebo (1.51 ± 0.98 mm) ( P < 0.001), while CAL gain was significant in the AZM group (2.71 ± 1.15 mm) as compared to the placebo group (1.71 ± 1.29 mm) ( P < 0.001). There was also a statistically significant reduction in the number of subjects positive for A. actinomycetemcomitans in the AZM group ( P < 0.0001). Conclusion Azithromycin was found to significantly improve the clinical and microbiological parameters in AAAP individuals. [ABSTRACT FROM AUTHOR]